AbbVie (ABBV) Resolves HUMIRA U.S. Litigation with Alvotech
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.6%
EPS Growth %: +107.5%
Join SI Premium – FREE
AbbVie (NYSE: ABBV) announced that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech.
Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive license to its HUMIRA-related patents in the United States, which will begin on July 1, 2023. AbbVie will make no payments of any form to Alvotech, and Alvotech will pay royalties to AbbVie for licensing its HUMIRA patents and acknowledges the validity and enforceability of the licensed patents. The resolution includes dismissal of the patent and trade secret litigation between AbbVie and Alvotech.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Art Newspaper expands into Asia with Hong Kong and China editions
- Atlassian and OpenAI expand partnership with GPT-6 models
- LiqTech wins first Finland pool filtration order in Helsinki
Create E-mail Alert Related Categories
Corporate News, LitigationRelated Entities
Twitter, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
